Refine by
Brain Disease Articles & Analysis
57 news found
This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, BBBporter™ enables the efficient transport of therapeutic candidates into the brain, opening new avenues for ...
Such properties include anti-inflammatory effects, promotion of brain health, and reduction of cardiovascular risk. Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...
The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected. Gantenerumab was well tolerated, including the subcutaneous administration. ...
His vast experience and proven track record will greatly support Elucid’s continued work in combating cardiovascular disease,” said Blake Richards, chief executive officer, Elucid. ...
ByElucid
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...
Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that their Cortical Disarray Measurement (CDM®) has been appointed as a secondary outcome measure for a Randomized, PlaceboControlled, Double-Blind Study of XPro™ in Patients ...
Since 2016, the Company has been developing a new drug, OKN-007, to treat brain cancers, especially, GBM as a rare disease and DIPG as a rare pediatric disease. ...
ByxCures
Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard electroencephalography (EEG) data to detect electrical disturbances in the brain that may predict cognitive decline and explain variability in disease course for patients with Alzheimer's disease. Pathmanathan's ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine ...
The miniseries was created with support from Altoida, a leading platform to improve drug development, research, and care for patients with neurological diseases including Alzheimer's. The launch coincides with the observation of Alzheimer's and Brain Awareness Month, and follows the successful pilot of the first Health Unmuted miniseries, COPD Podcast. ...
Kurve’s device is designed to deliver medication directly to the brain with disease-modifying clinical success and enhanced efficacy — while avoiding systemic side effects. Bypassing the blood-brain barrier (BBB) and nose-to-brain delivery have long been the elusive “holy grail” for the treatment of CNS ...
Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track Designation, as it recognizes the evidence demonstrating the potential for UB-311 to address a serious unmet medical need for patients with Alzheimer’s disease,” said Mei Mei Hu, Chief Executive Officer ...
ByVaxxinit
“The molecular heterogeneity of GBM is a key driver for the inconsistent therapy response rates that we see in brain cancer patients and makes the disease difficult to treat,” said Patrick Wen, MD, Director, Center for Neuro-oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; and Co-Principal Investigator for the ...
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. ...
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. ...
The article, “A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine,” outlines preliminary evidence suggesting UB-312 is well tolerated and induces dose-dependent antibody production, with high titer levels detectable in cerebrospinal fluid (CSF), a key characteristic for tackling diseases of the brain.¹ ...
ByVaxxinit
“Our research is exciting because while other devices require surgery that involves opening the skull, this brain-computer interface device is much less invasive. It receives electrical signals from the brain, allowing people to control a computer by ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other ...
Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an ...